



**EUROPEAN COMMISSION**  
JOINT RESEARCH CENTRE  
Directorate F – Health and Food  
Disease Prevention

**Annual Declaration of Interests<sup>1</sup> (DoI) form  
(v5, 26 January 2026)**

European Commission Initiative on Colorectal Cancer (ECICCC)

**Please answer each of the questions below.**

**If the answer to any of the questions is "Yes"<sup>2</sup>, please complete the corresponding fields, describing the circumstances, as appropriate.**

**If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the current ECICCC activities.**

**If you do not disclose relevant activities of interest for the ECICCC, your role may be revised.**

---

<sup>1</sup> According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form  
[https://ec.europa.eu/transparency/documents-register/detail?ref=C\(2016\)3301&lang=en](https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en)

<sup>2</sup> Answering "Yes" to the questions on this form does not automatically limit your participation in the ECICCC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (i.e. any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

**Name and Surname:**

**Prof. Dr. med. Graeven, Ullrich**

<b>Activities (2021-2025)</b>	<b>Yes/No</b>	<b>Period (From - To)</b>	<b>Information</b>	<b>Details</b>
<b>1. Do you have current investments<sup>3</sup> in a legal entity<sup>4</sup> with an interest related to colorectal cancer which either:</b> <ul style="list-style-type: none"><li>• has a value of more than 10.000 EUR,</li></ul> <b>or</b> <ul style="list-style-type: none"><li>• entitles you to a voting right of 5% or more?</li></ul>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please provide information about where the investment is placed (Name, Country, Public/Private).	[Please describe the entity and your role.]

<sup>3</sup> **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (e.g., proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

<sup>4</sup> **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
<p><b>2. Within the past 5 years, were you employed (remunerated post), have you had any other professional relationship with a legal entity, or held any non-remunerated post in a legal entity or any other body, with an interest related to colorectal cancer?</b></p> <p><b>A. Employment</b></p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYYY – MM/YYYYY	<p>If yes, please specify:</p> <ul style="list-style-type: none"> <li>• Name, Place of the entity;</li> <li>• Type of the entity: public, private, etc.;</li> <li>• The received amounts for remunerated activities.</li> </ul>	<p>[Please describe your role.]</p>

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
<b>B. Consultancy, including advisory activities</b>	Yes <input checked="" type="checkbox"/>	03/2021	Amgen, Germany, private 900 €	Advisory Board, Speaker, Chairman
	No <input type="checkbox"/>	06/2021	Amgen, Germany, private 1000 €	
		07/2021	MSD, Germany, private, 1500 €	
		10/2021	MSD, Germany, private, 1500 €	
		11/2021	Amgen, Germany, private 500 €	
		12/2021	MSD, Germany, private, 800 €	
		03/2022	AstraZeneca, Germany, private, 1800 €	
		03/2022	Novartis, Germany, private, 800 €	
		06/2022	Amgen, Germany, private, 900 €	
		10/2022	Amgen, Germany, private, 1200 €	
		11/2022	Amgen, Germany, private, 1200 €	
		12/2022	Ipsen, Germany private, 750 €	
		05/2023	AstraZeneca, Germany private, 1200 €	
	07/2023	Ipsen, Germany private, 940,00 €		
	10/2023	Merck Germany private, 1400,00 €		
	11/2023	Amgen Germany private, 1255,00 €		
	06/2024	Amgen Germany private, 1000,00 €		
	06/2024	Takeda Germany private, 1200,00 €		
	05/2025	BMS Geranny private 1100,00 €		
	08/2025	Servier Germany private 550,00 €		
	10/2025	Otsuka Germany private 1000.00 €		
	12/2025	Amgen Germany private 1250.00 €		
	12/2025	BeOne Germany private 1200,00 €		

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
<b>C. Non-remunerated post</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> <li>• Name, Place of the entity;</li> <li>• Type of the entity: public, private, etc.;</li> </ul>	Please describe your role.
<b>D. Legal representation<sup>5</sup></b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If yes, please specify: <ul style="list-style-type: none"> <li>• Name, Place of the entity;</li> <li>• Type of the entity: public, private, etc.;</li> </ul>	Please describe your role.

<sup>5</sup> **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

3. Regarding research related to colorectal cancer within the past 5 years:				
A. Have you been an investigator in research studies on colorectal cancer?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	07/2017-09/2021	Principal investigator for the site not for the study BEACON Study A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal  Study fees to the institution ARRAY, 13.926,67 €  Principal investigator for the site not for the study "A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer  Study fees to the institution MSD 15471,84 €	Published
		02/2022-05/2023		Published

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
<p><b>B. If yes, for the aforementioned research studies, did you receive support<sup>6</sup>?</b></p>	<p>Yes <input checked="" type="checkbox"/> No <input type="checkbox"/></p>	<p>02/2023-07/2024</p>	<p>Principal investigator for the site not for the study Kystal-10 A Randomized Phase 3 of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRS G12C Mutation with Disease Progression On or After Standard First-Line-Therapy</p> <p>Study fees to the institution Mirati 5000,00 €</p> <p>MAUNTENEER-03 An openlabel randomized Phase 3 Study of Tucatinib in combination with Trastuzumab and mFOLFOX6 versus FOLFOX6 given with or without either Cetuximab or Bevacuzumab as first-line treatment for subjects with HER2+ metastatic colorectal cancer Study fees to the institution Pfizer 4917,00 €</p>	<p>Not published</p>

<sup>6</sup> Support refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
<p>4. Do you have membership in national or international organisations<sup>7</sup>, including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in colorectal cancer?</p>	<p>Yes <input checked="" type="checkbox"/> No <input type="checkbox"/></p>	<p>01/2019 - ongoing</p>	<p>German Cancer Society</p>	<p>Member of the Board of Directors, Chairman of the certification committee for Cancer Centers, member of the certification committee for colorectal cancer centers</p>
<p>5. Do you have intellectual property rights (IPR)<sup>8</sup> related to colorectal cancer?</p>	<p>Yes <input type="checkbox"/> No <input checked="" type="checkbox"/></p>	<p>MM/YYYYY - MM/YYYYY</p>	<p>Please specify the title of the IPR.</p>	<p>Please describe the IPR.</p>
<p>6. Within the past 5 years:</p> <p>A. Have you provided any expert opinion or testimony in the field of colorectal cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?</p>	<p>Yes <input type="checkbox"/> No <input checked="" type="checkbox"/></p>	<p>MM/YYYYY - MM/YYYYY</p>	<p>Please mention the activity.</p>	<p>Please describe the activity.</p>

<sup>7</sup> Organisation refers to a governmental, international or non-profit organisation.

<sup>8</sup> Intellectual property rights refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021-2025)	Yes/No	Period (From - To)	Information	Details
<p><b>B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field colorectal cancer?</b></p>	<p>Yes <input type="checkbox"/> No <input checked="" type="checkbox"/></p>	<p>MM/YYYY – MM/YYYY</p>	<p>Please mention the activity.</p>	<p>Please describe the activity.</p>
<p><b>7. Do any of your immediate family members<sup>9</sup> have direct interests related to colorectal cancer that could undermine your independence?</b></p>	<p>Yes <input type="checkbox"/> No <input checked="" type="checkbox"/></p>	<p>MM/YYYY – MM/YYYY</p>	<p>Please mention the interest.</p>	<p>Please describe the interest.</p>
<p><b>8. Within the past 5 years, did you take part in other activities with interests related to colorectal cancer?</b></p>	<p>Yes <input checked="" type="checkbox"/> No <input type="checkbox"/></p>	<p>2017 ongoing</p>	<p>AWMF S3 Guide Line Colorectal Cancer</p>	<p>Coordinator for the chapter on advanced metastatic stages</p>

<sup>9</sup> Immediate family members refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

**Notes:**

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published<sup>10</sup> before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending a message as soon as possible to: [JRC-CANCER-POLICY-SUPPORT@ec.europa.eu](mailto:JRC-CANCER-POLICY-SUPPORT@ec.europa.eu).

- I hereby declare that the information disclosed in this form is true and complete to the best of my knowledge.
- I agree my DoI form to be publicly available on the JRC Healthcare Quality website, during the ECICC membership<sup>11</sup>.
- I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725<sup>12</sup>.

**Name and Surname:** Prof. Dr. med. Ullrich Graeven

**Date:** 10.02.2026

**Signature:**



**Place:** Mönchengladbach

---

<sup>10</sup> Personal data processing including the Declaration of Interests  
<https://ec.europa.eu/dpo-register/detail/DPR-EC-00656>

<sup>11</sup> Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

<sup>12</sup> Protection of individuals with regard to the processing of personal data  
<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725>